BioNTech SE ADR (BNTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BNTX POWR Grades
- Value is the dimension where BNTX ranks best; there it ranks ahead of 91.46% of US stocks.
- BNTX's strongest trending metric is Growth; it's been moving up over the last 52 weeks.
- BNTX's current lowest rank is in the Momentum metric (where it is better than 4.19% of US stocks).
BNTX Stock Summary
- With a year-over-year growth in debt of 387.96%, BioNTech SE's debt growth rate surpasses 97.05% of about US stocks.
- Over the past twelve months, BNTX has reported earnings growth of -2,945.62%, putting it ahead of just 0.61% of US stocks in our set.
- Revenue growth over the past 12 months for BioNTech SE comes in at 8,157.54%, a number that bests 99.79% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to BioNTech SE are QURE, MRNS, MRNA, LBRDA, and MICT.
- Visit BNTX's SEC page to see the company's official filings. To visit the company's web site, go to www.biontech.de.
BNTX Stock Price Chart Interactive Chart >
BNTX Price/Volume Stats
| Current price | $348.00 | 52-week high | $464.00 |
| Prev. close | $304.76 | 52-week low | $80.55 |
| Day low | $335.04 | Volume | 11,028,900 |
| Day high | $372.49 | Avg. volume | 3,145,802 |
| 50-day MA | $277.17 | Dividend yield | N/A |
| 200-day MA | $231.74 | Market Cap | 84.40B |
BioNTech SE ADR (BNTX) Company Bio
BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.
Latest BNTX News From Around the Web
Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
'Everyone is a little bit confused' about COVID-19 vaccine mandates and rules: DoctorDr. James Simmons, Hospitalist Nurse Practitioner joins Yahoo Finance’s Alexis Christoforous to discuss on holiday gatherings amid rising COVID-19 cases and the potential "double whammy" amid flu season. |
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal StudyCureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline Plc (NYSE: GSK), in the journal Nature. Related Link: CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study. The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNT |
CureVac Stock Climbs as Early Data Show Hope for Second Try at Covid VaccineA test in monkeys showed a response comparable to that from Pfizer's Covid-19 vaccine, according to a study published in a scientific journal. |
3 Biotech Stocks That Have More Than Tripled so far This YearHere's what they had to say about Cassava Sciences (NASDAQ: SAVA), Ocugen (NASDAQ: OCGN), and BioNTech (NASDAQ: BNTX). Prosper Junior Bakiny (Cassava Sciences): Shares of Cassava Sciences have soared by roughly 800% since the beginning of the year -- a terrific performance and one which the company owes to Simufilam, an investigational medicine for the treatment of Alzheimer's disease (AD). Positive data from an open-label study for the company's leading candidate, coupled with the unexpected approval of Biogen's AD drug Aduhelm, helped propel Cassava Sciences stock this year. |
'There will be another pandemic' and we need to be prepared when it comes: DoctorEmergency Medicine Physician Dr. Hiral Tipirneni speaks with Yahoo Finance’s Alexis Christoforous and Karina Mitchell about how Americans must still take precautions when spending their holidays indoors with family amid the ongoing pandemic. |
BNTX Price Returns
| 1-mo | 24.85% |
| 3-mo | 0.87% |
| 6-mo | 68.82% |
| 1-year | 216.39% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 326.89% |
| 2020 | 140.61% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...